Loading organizations...
Cyteir Therapeutics was a Lexington, Massachusetts-based clinical-stage biotechnology company that developed precision oncology therapies targeting cancer cell metabolism and DNA damage response biology. The organization focused on treating patients with advanced ovarian cancer and solid tumors through its lead drug candidate, CYT-0851, an oral monocarboxylate transporter inhibitor that reached Phase 1/2 clinical trials. Before announcing its dissolution in 2023 due to insufficient clinical data and capital, the firm collaborated with The Jackson Laboratory and operated under the leadership of executives including Markus Renschler and Donald Corcoran. The enterprise secured at least $34.5 million in private venture capital funding, including a $5.5 million Series A and a $29 million Series B, before filing for a $100 million initial public offering in 2021. Cyteir Therapeutics was originally founded in 2012 by Kevin Mills and Aubrey Watkins.
Cyteir Therapeutics has raised $156.5M across 5 funding rounds.
Cyteir Therapeutics has raised $156.5M in total across 5 funding rounds.
Cyteir Therapeutics has raised $156.5M across 5 funding rounds. Most recently, it raised $80.0M Series C in February 2021.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Feb 1, 2021 | $80M Series C | Derek Dirocco | Advanced Technology Ventures, Aisling Capital, Dolby Family Ventures, Novo Ventures, Venrock, Acuta Capital Partners, Ally Bridge Group, Ample Plus Fund, Avidity Partners, Caas Capital Management, Droia Ventures, Janus Henderson Investors, Lightstone Ventures, Osage University Partners | Announced |
| Oct 1, 2019 | $40M Series B | Novo Ventures | Advanced Technology Ventures, Aisling Capital, RA Capital, Venrock, Celgene, Droia Ventures, Lightstone Ventures, Osage University Partners | Announced |
| Mar 1, 2018 | $29M Series B | Venrock | Advanced Technology Ventures, Novo Ventures, RA Capital, Maria Palmisano, Bart VAN Hooland, Jean George | Announced |
| Jun 30, 2016 | $2M Grant | National Cancer Institute | — | Announced |
| Nov 5, 2015 | $5.5M Series A | Celgene | — | Announced |
Cyteir Therapeutics is a clinical‑stage biotechnology company developing precision oncology therapies; its lead program is CYT‑0851, an oral inhibitor of monocarboxylate transporters being tested in Phase 1/2 trials in solid tumors including advanced ovarian cancer[4][1].
High‑Level Overview
Origin Story
Core Differentiators
Role in the Broader Tech / Biotech Landscape
Quick Take & Future Outlook
Quick factual notes: Cyteir’s corporate website and regulatory/financial summaries identify the company as clinical‑stage, founded in 2012, headquartered in Lexington, MA, and focused on CYT‑0851 and precision oncology development[4][6][1].[4]
(If you’d like, I can compile recent clinical data releases, regulatory filings, or latest SEC/earnings materials to build a timeline of trial readouts and financial milestones.)
Cyteir Therapeutics has raised $156.5M in total across 5 funding rounds.
Cyteir Therapeutics's investors include Derek DiRocco, Advanced Technology Ventures, Aisling Capital, Dolby Family Ventures, Novo Ventures, Venrock, Acuta Capital Partners, Ally Bridge Group, Ample Plus Fund, Avidity Partners, CaaS Capital Management, Droia Ventures.